Japanese encephalitis: New options for active immunization

Clinical Infectious Diseases

Volumn 50, Issue 8, 2010, Pages 1155-1164

  Halstead, Scott B ^a   Thomas, Stephen J ^b  

^a Research Program   (United States)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIVAX JE; IC 51; INSECT REPELLENT; LIVE VACCINE; NEUTRALIZING ANTIBODY; SA 14142; UNCLASSIFIED DRUG; YELLOW FEVER VACCINE;

ACTIVE IMMUNIZATION; AUSTRALIA; CHINESE; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC ENCEPHALITIS; EUROPE; HEALTH CARE ACCESS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RISK; LICENSING; MORBIDITY; MORTALITY; POPULATION; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; SINGLE DRUG DOSE; THAILAND; TRAVEL; UNITED STATES; VACCINATION; VIREMIA; VIRUS ATTENUATION; VIRUS INACTIVATION; YELLOW FEVER;

ANIMALS; ASIA; AUSTRALIA; ENCEPHALITIS, JAPANESE; EUROPE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; MICE; UNITED STATES; VACCINES, ATTENUATED; VACCINES, COMBINED; VACCINES, INACTIVATED;

EID: 77950208765     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/651271     Document Type: Review

References (86)

1. Kari K, Liu W, Gautama K, et al. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med 2006; 4: 8.
2. Solomon T. Flavivirus encephalitis. N Engl J Med 2004; 351(4): 370-378.
3. Halstead S, Jacobson J. Japanese encephalitis vaccines Vaccines. 5th ed. Philadelphia Elsevier, 2008: 311-352.
4. World Health Organization. World Health Statistics. 2009. http://www.who.int/whosis/whostat/EN-WHS09-Full.pdf. Accessed 26 August 2009.
5. Halstead SB, Grosz CR. Subclinical Japanese encephalitis. 1. Infection of Americans with limited residence in Korea. Am J Hyg 1962; 75: 190-201.
6. Benenson MW, Top FH Jr, Gresso W, Ames CW, Altstart LB. The virulence to man of Japanese encephalitis virus in Thailand. Am J Trop Med Hyg 1975; 24(6 Pt 1): 974-980.
7. Gajanana A, Thenmozhi V, Samuel PP, Reuben R. A community-based study of subclinical flavivirus infections in children in an area of Tamil Nadu, India, where Japanese encephalitis is endemic. Bull World Health Organ 1995; 73(2): 237-244.
8. Gyure KA. West Nile virus infections. J Neuropathol Exp Neurol 2009; 68(10): 1053-1060.
9. Burke DS, Monath T. Flaviviruses. In: Knipe DM, Howley PM, eds. Fields Virology. Fourth ed Vol. 1. Philadelphia: Lippincott Williams & Wilkins, 2001: 1066-1072.
10. Grossman RA, Edelman R, Gould DJ. Study of Japanese encephalitis virus in Chiangmia Valley, Thailand. VI. Summary and conclusions. Am J Epidemiol 1974; 100(1): 69-76.
11. Edelman R, Schneider RJ, Chieowanich P, Pornpibul R, Voodhikul P. The effect of dengue virus infection on the clinical, sequelae of Japanese encephalitis: a one year follow-up study in Thailand. Southeast Asian J Trop Med Public Health 1975; 6(3): 308-315.
12. Hammon WM, Tigertt WD, Sather GE, Berge TO, Meiklejohn G. Epidemiologic studies of concurrent virgin epidemics of Japanese B encephalitis and of mumps on Guam, 1947-1948, with subsequent observations including dengue, through 1957. Am J Trop Med Hyg 1958; 7(4): 441-467.
13. Tarr GC, Hammon WM. Cross-protection between group B arboviruses: resistance in mice to Japanese B encephalitis and St. Louis encephalitis viruses induced by Dengue virus immunization. Infect Immun 1974; 9(5): 909-915.
14. Libraty DH, Nisalak A, Endy TP, Suntayakorn S, Vaughn DW, Innis BL. Clinical and immunological, risk factors for severe disease in Japanese encephalitis. Trans R Soc Trop Med Hyg 2002; 96(2): 173-178.
15. Tsai TR. Flaviviruses (yellow fever, dengue, dengue hemorrhagic fever, Japanese encephalitis, St. Louis encephalitis, tick-borne encephalitis). In: Mandeli GL, Bennett JE, R. D, eds. Principals and practice of infectious diseases. 5th ed Vol. 2. Philadelphia: Churchill Livingstone, 2000: 1727-1728.
16. Solomon T, Vaughn DW. Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr Top Microbiol Immunol 2002; 267: 171-194.
17. Solomon T, Dung NM, Kneen R, et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain 2002; 125(Pt 5): 1084-1093.
18. Dickerson RB, Newton JR, Hansen JE. Diagnosis and immediate prognosis of Japanese B encephalitis; observations based on more than 200 patients with detailed analysis of 65 serologically confirmed cases. Am J Med 1952; 12(3): 277-288.
19. Kimura K, Dosaka A, Hashimoto Y, Yasunaga T, Uchino M, Ando M. Single-photon emission CT findings in acute Japanese encephalitis. AJNR Am J Neuroradiol 1997; 18(3): 465-469.
20. Misra UK, Kalita J, Jain SK, Mathur A. Radiological and neurophysiological changes in Japanese encephalitis. J Neurol Neurosurg Psychiatry 1994; 57(12): 1484-1487.
21. Kumar R, Mathur A, Singh KB, et al. Clinical sequelae of Japanese encephalitis in children. Indian J Med Res 1993; 97: 9-13.
22. Tsai TR, Solomon T, D. V. Flaviviruses (yellow fever, dengue, dengue hemorrhagic fever, Japanese encephalitis, West Nile, St. Louis encephalitis, tick-borne encephalitis). In: Mandeli GL, Bennett JE, R. D, eds. Principals and practice of infectious diseases. 6th ed. Philadelphia: Elsevier, 2004: 1926-1950.
23. Harinasuta C, Nimmanitya S, Titsyakorn U. The effect of interferonalpha A on two cases of Japanese encephalitis in Thailand. Southeast Asian J Trop Med Public Health 1985; 16(2): 332-336.
24. Kumar R, Tripathi P, Baranwal M, Singh S, Tripathi S, Banerjee G. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin Infect Dis 2009; 48(4): 400-406.
25. Luo D, Yao R, Song J, Huo H, Wang Z. The effect of DDT spraying and bed nets impregnated with pyrethroid insecticide on the incidence of Japanese encephalitis virus infection. Trans R Soc Trop Med Hyg 1994; 88(6): 629-631.
26. Luo D, Zhang K, Song J, et al. The protective effect of bed nets impregnated with pyrethroid insecticide and vaccination against Japanese encephalitis. Trans R Soc Trop Med Hyg 1994; 88(6): 632-634.
27. Srivastava AK, Aira Y, Mori C, Kobayashi Y, Igarashi A. Antigenicity of Japanese encephalitis virus envelope glycoprotein V3 (E) and its cyanogen bromide cleaved fragments examined by monoclonal antibodies and Western blotting. Arch Virol 1987; 96(1-2): 97-107.
28. Konishi E, Yamaoka M, Khin Sane W, Kurane I, Takada K, Mason PW. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J Virol 1999; 73(7): 5527-5534.
29. Sukhavachana P, Yuill TM, Russell PK. Assay of arbovirus neutralizing antibody by micro methods. Trans R Soc Trop Med Hyg 1969; 63(4): 446-455.
30. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 2000; 18(Suppl 2): 26-32.
31. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005; 23(45): 5205-5211.
32. Hoke CH, Nisalak A, Sangawhipa N, et al. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 1988; 319(10): 608-614.
33. Paulke-Korinek M, Kollaritsch H. Japanese encephalitis and vaccines: past and future prospects. Wien Klin Wochenschr 2008; 120(19-20 Suppl 4): 15-19.
34. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin Biol Ther 2009; 9(7): 921-931.
35. Japanese encephalitis vaccines. Wkly Epidemiol Rec 2006; 81(34/35): 331-340.
36. Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst Rev 2007; (3): CD004263.
37. Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev Vaccines 2008; 7(5): 689-693.
38. National Travel Health Network and Centre. Travel health information sheet: Japanese encephalitis. July 2008. http://www.nathnac.org/travel/ factsheets/japanese-enc.htm. Accessed 26 December 2009.
39. Masta Travel Health, http://www.masta-travel-health.com/. Accessed 26 December 2009.
40. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Rccomm Rep 1993; 42(RR-1): 1-15.
41. Global Advisory Committee on Vaccine Safety, 9-10 June 2005. Wkly Epidemiol Rec 2005; 80(28): 242-247.
42. Beasley DW, Lewthwaite P, Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin Biol Ther 2008; 8(1): 95-106.
43. Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine. Lancet 1991; 337(8748): 1044.
44. Ruff TA, Eisen D, Fuller A, Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 1991; 338(8771): 881-882.
45. Halstead S, TR T. Japanese Encephalitis Vaccines. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines. Fourth ed. Philadelphia: Elsevier, 2004: 919-958.
46. Oya A. Japanese encephalitis vaccine. Acta Paediatr Jpn 1988; 30(2): 175-184.
47. Hennessy S, Liu Z, Tsai TF, et al. Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet 1996; 347(9015): 1583-1586.
48. Liu ZL, Hennessy S, Strom BL, et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 1997; 176(5): 1366-1369.
49. Tsai TF, Yu YX, Jia LL, et al. Immunogenicity of live attenuated SA14-14-2 Japanese encephalitis vaccine-a comparison of 1- and 3-month immunization schedules. J Infect Dis 1998; 177(1): 221-223.
50. Kumar R, Tripathi P, Rizvi. A. Effectiveness of one dose of SA 14-14-2 vaccine against Japanese encephalitis. N Engl J Med 2009; 360(14): 1465-1466.
51. Guidelines for the production and control of Japanese encephalitis vaccine (live) for humna use. Geneva: World Health Organization, 2002.
52. Bista MB, Banerjee MK, Shin SH, et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 2001; 358(9284): 791-795.
53. Ohrr H, Tandan JB, Sohn YM, Shin SH, Pradhan DP, Halstead SB. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 2005; 366(9494): 1375-1378.
54. Tandan JB, Ohrr H, Sohn YM, et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007; 25(27): 5041-5045.
55. Gatchalian S, Yao Y, Zhou B, et al. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine 2008; 26(18): 2234-2241.
56. Solomon T. Control of Japanese encephalitis-within our grasp? N Engl J Med 2006; 355(9): 869-871.
57. World Health Organization Department of Immunization, Vaccines and Biologicals. Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies. 2006. http://whqlibdoc.who. int/hq/2006/WHO-IVB-05.19-eng.pdf. Accessed 26 August 2009.
58. PATH. Japanese Encephalitis Project, http://www.path.org/projects/ japanese-encephalitis-project.php. Accessed 22 December 2009.
59. Putnak R, Barvir DA, Burrous JM, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174(6): 1176-1184.
60. Eckels KH, Yu YX, Dubois DR, Marchette NJ, Trent DW, Johnson AJ. Japanese encephalitis virus live-attenuated vaccine, Chinese strain SA14-14-2; adaptation to primary canine kidney cell cultures and preparation of a vaccine for human use. Vaccine 1988; 6(6): 513-518.
61. Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 1989; 70: 27-47.
62. Montagnon BJ, Fanget B, Nicolas AJ. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production: preliminary results for killed poliovirus vaccine. Dev Biol Stand 1981; 47: 55-64.
63. Durcux B, Canton P, Gerard A, et al. Rabies vaccine for human use, cultivated on Vero cells. Lancet 1986; 2(8498) :98.
64. Srivastava AK, Putnak JR, Lee SH, et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 2001; 19(31): 4557-4565.
65. Lyons A, Kanesa-thasan N, Kuschner RA, et al. A phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 2007; 25(17): 3445-3453.
66. Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370(9602): 1847-1853.
67. Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, doubleblind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008; 198(4): 493-499.
68. Schuller E, Jilma B, Voicu V, et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008; 26(34): 4382-4386.
69. Schuller E, Klade CS, Wolfl G, Kaltenbock A, Dewasthaly S, Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 2009; 27(15): 2188-2193.
70. Schuller E, Klade CS, Heinz FX, et al. Effect of pre-existing anti-tickborne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008; 26(48): 6151-6156.
71. Kaltenbock A, Dubischar-Kastner K, Eder G, et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled phase 3 study. Vaccine 2009; 27(33): 4483-4489.
72. Intercell. Japanese encephalitis vaccine, http://www.intercell.com/main/ forvaccperts/products/japanese-cncephalitis-vaccinc/. Accessed 26 August 2009
73. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999; 73(4): 3095-3101.
74. Konishi E, Yamaoka M, Khin Sane W, Kurane I, Mason PW. Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J Virol 1998; 72(6): 4925-4930.
75. Monath TP, Levenbook I, Soike K, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 2000; 74(4): 1742-1751.
76. Monath TP, Soike K, Levenbook I, et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 1999; 17(15-16): 1869-1882.
77. Bhatt TR, Crabtree MB, Guirakhoo F, Monath TP, Miller BR. Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14-14-2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg 2000; 62(4): 480-484.
78. Reid M, Mackenzie D, Baron A, et al. Experimental infection of Culex annulirostris, Culex gelidus, and Aedes vigilax with a yellow fever/Japanese encephalitis virus vaccine chimera (ChimeriVax-JE). Am J Trop Med Hyg 2006; 75(4): 659-663.
79. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivims infections. Vaccine 2002; 20(7-8): 1004-1018.
80. Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003; 188(8): 1213-1230.
81. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2009; 28(3): 632-649.
82. Sanofi Pasteur, http://www.sanofipasteur.com/sanofi-pasteur2/front/index. jsp?siteCode = SP-CORP&codeRubrique = 34. Access 25 August 2009.
83. Centers for Disease Control and Prevention. ACIP provisional recommendations. http://www.cdc.gOv/vaccines/recs/provisional/#acip. Accessed 25 August 2009.
84. Burchard GD, Caumes E, Connor BA, et al. Expert opinion on vaccination of travelers against Japanese encephalitis. J Travel Med 2009; 16(3): 204-216.
85. Hatz C, Werlein J, Mutsch M, Hufnagel M, Behrens RH. Japanese encephalitis: defining risk incidence for travelers to endemic countries and vaccine prescribing from the UK and Switzerland. J Travel Med 2009; 16(3): 200-203.
86. Expert opinion on vaccination of travelers against Japanese encephalitis. J Travel Med 2009; 16(6): 441-443.